{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T14:42:00Z","timestamp":1793457720076,"version":"4.5.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T00:00:00Z","timestamp":1764288000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T00:00:00Z","timestamp":1764288000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s00259-025-07682-5","type":"journal-article","created":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T03:57:45Z","timestamp":1764302265000},"page":"3034-3041","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Comparison of mCRPC [177Lu]Lu-PSMA-617 radioligand therapy with and without concurrent enzalutamide medication in a real-world setting"],"prefix":"10.1007","volume":"53","author":[{"given":"Florian","family":"Rosar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fadi","family":"Khreish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Burgard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Artyom","family":"Fursov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arne","family":"Blickle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Bartholom\u00e4","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Maus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moritz B.","family":"Bastian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tilman","family":"Speicher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Schaefer-Schuler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4110-3375","authenticated-orcid":false,"given":"Samer","family":"Ezziddin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,28]]},"reference":[{"key":"7682_CR1","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.eururo.2023.04.021","volume":"84","author":"O Bergengren","year":"2023","unstructured":"Bergengren O, Pekala KR, Matsoukas K, Fainberg J, Mungovan SF, Bratt O, et al. 2022 update on prostate cancer epidemiology and risk Factors-A systematic review. Eur Urol. 2023;84:191\u2013206. https:\/\/doi.org\/10.1016\/j.eururo.2023.04.021.","journal-title":"Eur Urol"},{"key":"7682_CR2","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1111\/j.1742-1241.2011.02799.x","volume":"65","author":"M Kirby","year":"2011","unstructured":"Kirby M, Hirst C, Crawford ED. Characterising the castration-resistant prostate cancer population: a systematic review. Int J Clin Pract. 2011;65:1180\u201392. https:\/\/doi.org\/10.1111\/j.1742-1241.2011.02799.x.","journal-title":"Int J Clin Pract"},{"key":"7682_CR3","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1038\/nrc4016","volume":"15","author":"PA Watson","year":"2015","unstructured":"Watson PA, Arora VK, Sawyers CL. Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer. Nat Rev Cancer. 2015;15:701\u201311. https:\/\/doi.org\/10.1038\/nrc4016.","journal-title":"Nat Rev Cancer"},{"key":"7682_CR4","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1056\/NEJMoa040720","volume":"351","author":"IF Tannock","year":"2004","unstructured":"Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or Mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502\u201312. https:\/\/doi.org\/10.1056\/NEJMoa040720.","journal-title":"N Engl J Med"},{"key":"7682_CR5","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/S0140-6736(10)61389-X","volume":"376","author":"JS de Bono","year":"2010","unstructured":"de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels J-P, Kocak I, et al. Prednisone plus Cabazitaxel or Mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010;376:1147\u201354. https:\/\/doi.org\/10.1016\/S0140-6736(10)61389-X.","journal-title":"Lancet"},{"key":"7682_CR6","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","volume":"364","author":"JS de Bono","year":"2011","unstructured":"de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364:1995\u20132005. https:\/\/doi.org\/10.1056\/NEJMoa1014618.","journal-title":"N Engl J Med"},{"key":"7682_CR7","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","volume":"367","author":"HI Scher","year":"2012","unstructured":"Scher HI, Fizazi K, Saad F, Taplin M-E, Sternberg CN, Miller K, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367:1187\u201397. https:\/\/doi.org\/10.1056\/NEJMoa1207506.","journal-title":"N Engl J Med"},{"key":"7682_CR8","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","volume":"382","author":"J de Bono","year":"2020","unstructured":"de Bono J, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S, et al. Olaparib for metastatic Castration-Resistant prostate cancer. N Engl J Med. 2020;382:2091\u2013102. https:\/\/doi.org\/10.1056\/NEJMoa1911440.","journal-title":"N Engl J Med"},{"key":"7682_CR9","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1056\/NEJMoa1213755","volume":"369","author":"C Parker","year":"2013","unstructured":"Parker C, Nilsson S, Heinrich D, Helle SI, O\u2019Sullivan JM, Foss\u00e5 SD, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369:213\u201323. https:\/\/doi.org\/10.1056\/NEJMoa1213755.","journal-title":"N Engl J Med"},{"key":"7682_CR10","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1055\/s-0043-1774733","volume":"22","author":"A Al-Ibraheem","year":"2023","unstructured":"Al-Ibraheem A. Theranostics in developing countries: addressing challenges and potentials from training to practice. World J Nucl Med. 2023;22:171\u20133. https:\/\/doi.org\/10.1055\/s-0043-1774733.","journal-title":"World J Nucl Med"},{"key":"7682_CR11","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.3390\/ph15101292","volume":"15","author":"U Hennrich","year":"2022","unstructured":"Hennrich U, Eder M. [177Lu]Lu-PSMA-617 (PluvictoTM): the first FDA-Approved radiotherapeutical for treatment of prostate cancer. Pharmaceuticals (Basel). 2022;15:1292. https:\/\/doi.org\/10.3390\/ph15101292.","journal-title":"Pharmaceuticals (Basel)"},{"key":"7682_CR12","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1002\/jcb.10661","volume":"91","author":"A Ghosh","year":"2004","unstructured":"Ghosh A, Heston WDW. Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer. J Cell Biochem. 2004;91:528\u201339. https:\/\/doi.org\/10.1002\/jcb.10661.","journal-title":"J Cell Biochem"},{"issue":"19980601","key":"7682_CR13","doi-asserted-by":"publisher","first-page":"2256","DOI":"10.1002\/(SICI)1097-0142","volume":"82","author":"DG Bostwick","year":"1998","unstructured":"Bostwick DG, Pacelli A, Blute M, Roche P, Murphy GP. Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma. Cancer. 1998;82(19980601):2256\u201361. https:\/\/doi.org\/10.1002\/(SICI)1097-0142. )82:11%253C2256::AID-CNCR22%253E3.0.CO;2-S.","journal-title":"Cancer"},{"key":"7682_CR14","first-page":"81","volume":"3","author":"DA Silver","year":"1997","unstructured":"Silver DA, Pellicer I, Fair WR, Heston WD, Cordon-Cardo C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res. 1997;3:81\u20135.","journal-title":"Clin Cancer Res"},{"key":"7682_CR15","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1007\/s00259-021-05525-7","volume":"49","author":"F Khreish","year":"2022","unstructured":"Khreish F, Ghazal Z, Marlowe RJ, Rosar F, Sabet A, Maus S, et al. 177Lu-PSMA-617 radioligand therapy of metastatic castration-resistant prostate cancer: initial 254-patient results from a prospective registry (REALITY Study). Eur J Nucl Med Mol Imaging. 2022;49:1075\u201385. https:\/\/doi.org\/10.1007\/s00259-021-05525-7.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7682_CR16","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/S0140-6736(21)00237-3","volume":"397","author":"MS Hofman","year":"2021","unstructured":"Hofman MS, Emmett L, Sandhu S, Iravani A, Joshua AM, Goh JC, et al. [177Lu]Lu-PSMA-617 versus Cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. Lancet. 2021;397:797\u2013804. https:\/\/doi.org\/10.1016\/S0140-6736(21)00237-3.","journal-title":"Lancet"},{"key":"7682_CR17","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1007\/s11523-021-00801-w","volume":"16","author":"D Meyrick","year":"2021","unstructured":"Meyrick D, Gallyamov M, Sabarimurugan S, Falzone N, Lenzo N. Real-World data analysis of efficacy and survival after Lutetium-177 labelled PSMA ligand therapy in metastatic Castration-Resistant prostate cancer. Target Oncol. 2021;16:369\u201380. https:\/\/doi.org\/10.1007\/s11523-021-00801-w.","journal-title":"Target Oncol"},{"key":"7682_CR18","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","volume":"385","author":"O Sartor","year":"2021","unstructured":"Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, et al. Lutetium-177-PSMA-617 for metastatic Castration-Resistant prostate cancer. N Engl J Med. 2021;385:1091\u2013103. https:\/\/doi.org\/10.1056\/NEJMoa2107322.","journal-title":"N Engl J Med"},{"key":"7682_CR19","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/S1470-2045(18)30198-0","volume":"19","author":"MS Hofman","year":"2018","unstructured":"Hofman MS, Violet J, Hicks RJ, Ferdinandus J, Thang SP, Akhurst T, et al. [177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study. Lancet Oncol. 2018;19:825\u201333. https:\/\/doi.org\/10.1016\/S1470-2045(18)30198-0.","journal-title":"Lancet Oncol"},{"key":"7682_CR20","doi-asserted-by":"publisher","first-page":"85","DOI":"10.2967\/jnumed.116.183194","volume":"58","author":"K Rahbar","year":"2017","unstructured":"Rahbar K, Ahmadzadehfar H, Kratochwil C, Haberkorn U, Sch\u00e4fers M, Essler M, et al. German multicenter study investigating 177Lu-PSMA-617 radioligand therapy in advanced prostate cancer patients. J Nucl Med. 2017;58:85\u201390. https:\/\/doi.org\/10.2967\/jnumed.116.183194.","journal-title":"J Nucl Med"},{"key":"7682_CR21","doi-asserted-by":"publisher","first-page":"7812","DOI":"10.7150\/thno.47251","volume":"10","author":"R Seifert","year":"2020","unstructured":"Seifert R, Seitzer K, Herrmann K, Kessel K, Sch\u00e4fers M, Kleesiek J, et al. Analysis of PSMA expression and outcome in patients with advanced prostate cancer receiving 177Lu-PSMA-617 radioligand therapy. Theranostics. 2020;10:7812\u201320. https:\/\/doi.org\/10.7150\/thno.47251.","journal-title":"Theranostics"},{"key":"7682_CR22","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s00259-019-04529-8","volume":"47","author":"S Vaz","year":"2020","unstructured":"Vaz S, Hadaschik B, Gabriel M, Herrmann K, Eiber M, Costa D. Influence of androgen deprivation therapy on PSMA expression and PSMA-ligand PET imaging of prostate cancer patients. Eur J Nucl Med Mol Imaging. 2020;47:9\u201315. https:\/\/doi.org\/10.1007\/s00259-019-04529-8.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7682_CR23","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1007\/s13139-016-0439-4","volume":"51","author":"MK Bakht","year":"2017","unstructured":"Bakht MK, Oh SW, Youn H, Cheon GJ, Kwak C, Kang KW. Influence of androgen deprivation therapy on the uptake of PSMA-Targeted agents: emerging opportunities and challenges. Nucl Med Mol Imaging. 2017;51:202\u201311. https:\/\/doi.org\/10.1007\/s13139-016-0439-4.","journal-title":"Nucl Med Mol Imaging"},{"key":"7682_CR24","doi-asserted-by":"publisher","first-page":"7431","DOI":"10.3390\/ijms22147431","volume":"22","author":"M Staniszewska","year":"2021","unstructured":"Staniszewska M, Fragoso Costa P, Eiber M, Klose JM, Wosniack J, Reis H, et al. Enzalutamide enhances PSMA expression of PSMA-Low prostate cancer. Int J Mol Sci Multidisciplinary Digit Publishing Inst. 2021;22:7431. https:\/\/doi.org\/10.3390\/ijms22147431.","journal-title":"Int J Mol Sci Multidisciplinary Digit Publishing Inst"},{"key":"7682_CR25","doi-asserted-by":"publisher","first-page":"950","DOI":"10.2967\/jnumed.118.223099","volume":"60","author":"L Emmett","year":"2019","unstructured":"Emmett L, Yin C, Crumbaker M, Hruby G, Kneebone A, Epstein R, et al. Rapid modulation of PSMA expression by androgen deprivation: serial 68Ga-PSMA-11 PET in men with Hormone-Sensitive and Castrate-Resistant prostate cancer commencing androgen Blockade. J Nuclear Med Soc Nuclear Med. 2019;60:950\u20134. https:\/\/doi.org\/10.2967\/jnumed.118.223099.","journal-title":"J Nuclear Med Soc Nuclear Med"},{"key":"7682_CR26","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.euo.2018.03.010","volume":"1","author":"R Aggarwal","year":"2018","unstructured":"Aggarwal R, Wei X, Kim W, Small EJ, Ryan CJ, Carroll P, et al. Heterogeneous flare in prostate-specific membrane antigen positron emission tomography tracer uptake with initiation of androgen pathway Blockade in metastatic prostate cancer. Eur Urol Oncol. 2018;1:78\u201382. https:\/\/doi.org\/10.1016\/j.euo.2018.03.010.","journal-title":"Eur Urol Oncol"},{"key":"7682_CR27","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1002\/pros.23522","volume":"78","author":"B Kranzb\u00fchler","year":"2018","unstructured":"Kranzb\u00fchler B, Salemi S, Umbricht CA, M\u00fcller C, Burger IA, Sulser T, et al. Pharmacological upregulation of prostate-specific membrane antigen (PSMA) expression in prostate cancer cells. Prostate. 2018;78:758\u201365. https:\/\/doi.org\/10.1002\/pros.23522.","journal-title":"Prostate"},{"key":"7682_CR28","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s13550-018-0451-z","volume":"8","author":"K L\u00fcckerath","year":"2018","unstructured":"L\u00fcckerath K, Wei L, Fendler WP, Evans-Axelsson S, Stuparu AD, Slavik R, et al. Preclinical evaluation of PSMA expression in response to androgen receptor Blockade for theranostics in prostate cancer. EJNMMI Res. 2018;8:96. https:\/\/doi.org\/10.1186\/s13550-018-0451-z.","journal-title":"EJNMMI Res"},{"key":"7682_CR29","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1002\/pros.22910","volume":"75","author":"JD Murga","year":"2015","unstructured":"Murga JD, Moorji SM, Han AQ, Magargal WW, DiPippo VA, Olson WC. Synergistic co-targeting of prostate-specific membrane antigen and androgen receptor in prostate cancer. Prostate. 2015;75:242\u201354. https:\/\/doi.org\/10.1002\/pros.22910.","journal-title":"Prostate"},{"key":"7682_CR30","doi-asserted-by":"publisher","unstructured":"Evans MJ, Smith-Jones PM, Wongvipat J, Navarro V, Kim S, Bander NH et al. Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigen. Proceedings of the National Academy of Sciences. Proceedings of the National Academy of Sciences; 2011;108:9578\u201382. https:\/\/doi.org\/10.1073\/pnas.1106383108","DOI":"10.1073\/pnas.1106383108"},{"key":"7682_CR31","doi-asserted-by":"publisher","first-page":"3700","DOI":"10.1007\/s00259-025-07178-2","volume":"52","author":"LM Unterrainer","year":"2025","unstructured":"Unterrainer LM, Farolfi A, Grogan T, Hotta M, Djaileb L, Gafita A, et al. Early changes of PSMA PET expression after initiation of androgen receptor signaling inhibitors in CRPC: an international multicenter retrospective study. Eur J Nucl Med Mol Imaging. 2025;52:3700\u20138. https:\/\/doi.org\/10.1007\/s00259-025-07178-2.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7682_CR32","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1007\/s00259-019-04674-0","volume":"47","author":"F Rosar","year":"2020","unstructured":"Rosar F, Dewes S, Ries M, Schaefer A, Khreish F, Maus S, et al. New insights in the paradigm of upregulation of tumoral PSMA expression by androgen receptor blockade: enzalutamide induces PSMA upregulation in castration-resistant prostate cancer even in patients having previously progressed on enzalutamide. Eur J Nucl Med Mol Imaging. 2020;47:687\u201394. https:\/\/doi.org\/10.1007\/s00259-019-04674-0.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7682_CR33","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.3390\/cancers14071696","volume":"14","author":"F Rosar","year":"2022","unstructured":"Rosar F, Neher R, Burgard C, Linxweiler J, Schreckenberger M, Hoffmann MA, et al. Upregulation of PSMA expression by enzalutamide in patients with advanced mCRPC. Cancers. Multidisciplinary Digit Publishing Inst. 2022;14:1696. https:\/\/doi.org\/10.3390\/cancers14071696.","journal-title":"Multidisciplinary Digit Publishing Inst"},{"key":"7682_CR34","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/S1470-2045(24)00179-7","volume":"25","author":"N Hou\u00e9d\u00e9","year":"2024","unstructured":"Hou\u00e9d\u00e9 N, Hebert K. Combining enzalutamide and [177Lu]Lu-PSMA-617 in metastatic castration-resistant prostate cancer. Lancet Oncol. 2024;25:531\u20133. https:\/\/doi.org\/10.1016\/S1470-2045(24)00179-7.","journal-title":"Lancet Oncol"},{"key":"7682_CR35","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.eururo.2019.06.030","volume":"76","author":"A Paschalis","year":"2019","unstructured":"Paschalis A, Sheehan B, Riisnaes R, Rodrigues DN, Gurel B, Bertan C, et al. Prostate-specific membrane antigen heterogeneity and DNA repair defects in prostate cancer. Eur Urol. 2019;76:469\u201378. https:\/\/doi.org\/10.1016\/j.eururo.2019.06.030.","journal-title":"Eur Urol"},{"key":"7682_CR36","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.2967\/jnumed.124.268020","volume":"65","author":"F Pouliot","year":"2024","unstructured":"Pouliot F, Saad F, Rousseau E, Richard PO, Zamanian A, Probst S, et al. Intrapatient intermetastatic heterogeneity determined by Triple-Tracer PET imaging in mCRPC patients and correlation to survival: the 3TMPO cohort study. J Nucl Med. 2024;65:1710\u20137. https:\/\/doi.org\/10.2967\/jnumed.124.268020.","journal-title":"J Nucl Med"},{"key":"7682_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.canlet.2021.06.006","volume":"518","author":"A Jamroze","year":"2021","unstructured":"Jamroze A, Chatta G, Tang DG. Androgen receptor (AR) heterogeneity in prostate cancer and therapy resistance. Cancer Lett. 2021;518:1\u20139. https:\/\/doi.org\/10.1016\/j.canlet.2021.06.006.","journal-title":"Cancer Lett"},{"key":"7682_CR38","doi-asserted-by":"publisher","first-page":"23902","DOI":"10.1038\/s41598-025-06393-z","volume":"15","author":"Y Mulati","year":"2025","unstructured":"Mulati Y, Shen Q, Tian Y, Chen Y, Yao K, Yu W, et al. Characterizing PSMA heterogeneity in prostate cancer and identifying clinically actionable tumor associated antigens in PSMA negative cases. Sci Rep. 2025;15:23902. https:\/\/doi.org\/10.1038\/s41598-025-06393-z.","journal-title":"Sci Rep"},{"key":"7682_CR39","doi-asserted-by":"publisher","first-page":"2691","DOI":"10.3390\/cancers14112691","volume":"14","author":"F Rosar","year":"2022","unstructured":"Rosar F, Bader H, Bartholom\u00e4 M, Maus S, Burgard C, Linxweiler J, et al. Addition of standard enzalutamide medication shows synergistic effects on response to [177Lu]Lu-PSMA-617 radioligand therapy in mCRPC patients with imminent treatment Failure-Preliminary evidence of pilot experience. Cancers (Basel). 2022;14:2691. https:\/\/doi.org\/10.3390\/cancers14112691.","journal-title":"Cancers (Basel)"},{"key":"7682_CR40","doi-asserted-by":"publisher","unstructured":"Muniz M, Sartor O, Orme JJ, Koch RM, Scharf Z, Heath EI, et al. Outcomes for [177Lu]Lu-PSMA-617 with and without concurrent use of androgen receptor pathway inhibitors in patients with metastatic Castration-resistant prostate cancer. Eur Urol Oncol. 2025;S2588-9311(25)00175-0. https:\/\/doi.org\/10.1016\/j.euo.2025.06.004.","DOI":"10.1016\/j.euo.2025.06.004"},{"key":"7682_CR41","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/S1470-2045(24)00135-9","volume":"25","author":"L Emmett","year":"2024","unstructured":"Emmett L, Subramaniam S, Crumbaker M, Nguyen A, Joshua AM, Weickhardt A, et al. [177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial. Lancet Oncol. 2024;25:563\u201371. https:\/\/doi.org\/10.1016\/S1470-2045(24)00135-9.","journal-title":"Lancet Oncol"},{"key":"7682_CR42","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/S1470-2045(25)00009-9","volume":"26","author":"L Emmett","year":"2025","unstructured":"Emmett L, Subramaniam S, Crumbaker M, Joshua AM, Sandhu S, Nguyen A, et al. Overall survival and quality of life with [177Lu]Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer (ENZA-p): secondary outcomes from a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol. 2025;26:291\u20139. https:\/\/doi.org\/10.1016\/S1470-2045(25)00009-9.","journal-title":"Lancet Oncol"},{"key":"7682_CR43","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1016\/j.annonc.2025.05.011","volume":"36","author":"B Tombal","year":"2025","unstructured":"Tombal B, Choudhury A, Saad F, Gallardo E, Soares A, Loriot Y, et al. Enzalutamide plus radium-223 in metastatic castration-resistant prostate cancer: results of the EORTC 1333\/PEACE-3 trial. Ann Oncol. 2025;36:1058\u201367. https:\/\/doi.org\/10.1016\/j.annonc.2025.05.011.","journal-title":"Ann Oncol"},{"key":"7682_CR44","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1056\/NEJMoa1405095","volume":"371","author":"TM Beer","year":"2014","unstructured":"Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014;371:424\u201333. https:\/\/doi.org\/10.1056\/NEJMoa1405095.","journal-title":"N Engl J Med"},{"key":"7682_CR45","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1056\/NEJMoa1903835","volume":"381","author":"ID Davis","year":"2019","unstructured":"Davis ID, Martin AJ, Stockler MR, Begbie S, Chi KN, Chowdhury S, et al. Enzalutamide with standard First-Line therapy in metastatic prostate cancer. New Engl J Med Mass Med Soc. 2019;381:121\u201331. https:\/\/doi.org\/10.1056\/NEJMoa1903835.","journal-title":"New Engl J Med Mass Med Soc"},{"key":"7682_CR46","doi-asserted-by":"publisher","first-page":"e546","DOI":"10.1016\/j.ijrobp.2024.07.1209","volume":"120","author":"H Kim","year":"2024","unstructured":"Kim H, Tagawa ST, Sartor AO, Saad F, Reid A, Sakharova O, et al. PSMAddition: phase 3 trial of [177Lu]Lu-PSMA-617 plus standard of care (SoC) vs. Soc alone in patients with metastatic Hormone-Sensitive prostate cancer. Int J Radiation Oncol Biology Phys Elsevier. 2024;120:e546. https:\/\/doi.org\/10.1016\/j.ijrobp.2024.07.1209.","journal-title":"Int J Radiation Oncol Biology Phys Elsevier"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07682-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-025-07682-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07682-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T01:26:23Z","timestamp":1774401983000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-025-07682-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,28]]},"references-count":46,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["7682"],"URL":"https:\/\/doi.org\/10.1007\/s00259-025-07682-5","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,28]]},"assertion":[{"value":"12 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in the patients described herein were in accordance with the ethical standards of the Institutional and\/or National Research Ethics Committees and with the 1964 Helsinki Declaration and its later amendments, or with comparable ethical standards. This report does not include any animal studies. The study was approved by the Institutional Review Board of \u00c4rztekammer des Saarlandes\/Saarbr\u00fccken (ethics committee permission number 140\/17). Written informed consent was obtained from all study participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All patients have given written consent to publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}